Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 206,119,889 papers from all fields of science
Search
Sign In
Create Free Account
everolimus 5 MG Tablet for Oral Suspension [Afinitor]
Known as:
Afinitor Disperz 5 MG Tablet for Oral Suspension
, EVEROLIMUS 5 mg ORAL TABLET, FOR SUSPENSION [Afinitor Disperz]
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
9 relations
Butylated Hydroxytoluene
Crospovidone
Lactose Monohydrate
Magnesium stearate
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Everolimus, lutetium-177 DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis.
R. Mújica-Mota
,
J. Varley-Campbell
,
+11 authors
M. Hoyle
Health technology assessment
2018
Corpus ID: 52194429
BACKGROUND Neuroendocrine tumours (NETs) are a group of heterogeneous cancers that develop in cells in the diffuse neuroendocrine…
Expand
2016
2016
Neue Therapieoptionen bei Neuroendokrinen Tumoren des Gastrointestinaltraktes
R. W. Lipp
,
P. Kump
2016
Corpus ID: 59454912
Recent therapy options of gastro- intestinal neuroendocrine tumours. Neuroen- docrine tumors (NET) of gastroenteropancreatic (GEP…
Expand
2016
2016
Everolimus downregulates estrogen receptor and induces autophagy in aromatase inhibitor-resistant breast cancer cells
A. Lui
,
J. New
,
Joshua Ogony
,
S. Thomas
,
J. Lewis-Wambi
BMC Cancer
2016
Corpus ID: 1027379
BackgroundmTOR inhibition of aromatase inhibitor (AI)-resistant breast cancer is currently under evaluation in the clinic…
Expand
2015
2015
In vitro activity of the mTOR inhibitor everolimus, in a large panel of breast cancer cell lines and analysis for predictors of response
S. Hurvitz
,
O. Kalous
,
+9 authors
D. Slamon
Breast Cancer Research and Treatment
2015
Corpus ID: 70797
Everolimus (RAD001, Afinitor®) is an oral, selective mTOR inhibitor recently approved by the US-FDA in combination with…
Expand
Review
2013
Review
2013
Everolimus in Combination with Exemestane: A Review of its Use in the Treatment of Patients with Postmenopausal Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Sohita Dhillon
Drugs
2013
Corpus ID: 3100316
Oral everolimus (Afinitor®) in combination with exemestane is indicated for the treatment of hormone receptor-positive, human…
Expand
Review
2013
Review
2013
Practical Management of Everolimus-Related Toxicities in Patients with Advanced Solid Tumors
V. Grünwald
,
S. Weikert
,
+5 authors
Matthias M. Weber
Oncology Research and Treatment
2013
Corpus ID: 207619866
Everolimus is an orally administered inhibitor of the mammalian target of rapamycin (mTOR), an intracellular protein kinase…
Expand
2012
2012
FDA Approves Everolimus (Afinitor Disperz) for Rare Pediatric Brain Tumor
Ian Ingram
2012
Corpus ID: 150027658
The FDA approved a dissolvable form of everolimus (Afinitor Disperz) for the treatment of children with subependymal giant cell…
Expand
2012
2012
Everolimus (Afinitor® or Votubia®) in combination with exemestane in postmenopausal women with oestrogen receptor positive, HER2-negative locally advanced or metastatic breast cancer who are…
K. Jeitler
,
T. Semlitsch
2012
Corpus ID: 68235303
In Austria, about 24% of women with initially diagnosed breast cancer (BC) have locally advanced and about 5% have metastatic…
Expand
2009
2009
Everolimus (Afinitor®), Trastuzumab (H), and Paclitaxel (P) or Vinorelbine (V) in the Treatment of HER-2+ Metastatic Breast Cancer (MBC) Patients (Pts) Pre-Treated with Lapatinib-Containing Therapy…
F. Cardoso
,
V. Diéras
,
+8 authors
L. Gianni
2009
Corpus ID: 71568351
Introduction: The re-introduction of H-based therapy after progression on a lapatinib-containing regimen has not yet been…
Expand
2009
2009
Everolimus (Afinitor®) for advanced/metastatic kidney cancer
A. Nachtnebel
2009
Corpus ID: 68182187
The purpose of this report was to evaluate efficacy and safety of second-line therapy with everolimus, an mTOR inhibitor, for the…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE